Compare BIO-TECHNE Corp (TECH) vs Zscaler Inc (ZS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BIO-TECHNE Corp vs Zscaler Inc — how do they compare? BIO-TECHNE Corp trades at $72.13 (market cap $11.24B), while Zscaler Inc trades at $178.13 (market cap $28.57B). The key difference: Zscaler Inc is far larger — about 2.5× BIO-TECHNE Corp's market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Zscaler Inc pays none. Which is the better fit depends on your goals.
| TECH | ZS | |
|---|---|---|
Market Cap | $11.24B | $28.57B |
Sector | Health | Technology |
52-Week High | $72.29 | $336.27 |
52-Week Low | $43.31 | $118.05 |
Enterprise Value | $11.32B | $26.89B |
Dividend Yield | 0.44% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
Zscaler (ZS) trades at $168.68, up 3.74% on the day, exhibiting strong bullish momentum with a consensus analyst price target of $191.81. The stock shows robust revenue growth, with fiscal 2025 revenue reaching $2.67 billion, though it remains unprofitable with a net income margin of -2.44%. Recent positive developments include being named a Leader in the 2026 Gartner Magic Quadrant for SASE and Security Service Edge, and consistently beating earnings expectations in recent quarters.
The outlook is cautiously optimistic, driven by strong secular trends in cybersecurity and Zero Trust adoption. The primary investment opportunity lies in the company's high revenue growth and market leadership. Key risks include persistent profitability challenges, high valuation multiples like an EV/EBITDA of 177.75, and intense competition in the cybersecurity sector. The stock's near-term performance will be heavily influenced by the upcoming Q2 2026 earnings report.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →About Zscaler Inc
Zscaler is a security-as-a-service firm that offers its customers cloud-delivered solutions for protecting user devices and data. The firm leverages its position in 150 colocation data centers to deliver traditionally appliance-based security functionality, such as firewalls and sandboxes, as a completely cloud-native platform. The firm focuses on large enterprise customers and offers two primary product suites: Zscaler Internet Access, which securely connects users to externally managed application and websites (such as Salesforce and Google), and Zscaler Private Access, which securely connects users to internally managed applications. Both product suites encompass a broad gamut of capabilities situated across the traditional security stack.
Read more on ZS →
